Genetic Technology Alert. Drug for Oculopharyngeal Muscular Dystrophy Treatment Receives Orphan Drug Designation; Non-Viral CFTR-Based Gene Therapy for Cystic Fibrosis Patients; Breast Cancer Diagnostic Test in Europe

RELEASE DATE
17-Jul-2015

REGION
Global

Research Code: D757-00-03-00-00

SKU: HC02733-GL-TA_19627

$250.00

Special Price $187.50 save 25 %

In stock

SKU

HC02733-GL-TA_19627

Skip to the end of the images gallery

Skip to the beginning of the images gallery

$250.00

$187.50 save 25 %

DownloadLink

downloadable link $0.00

Select all

Qty

Pay by invoice

ENQUIRE NOW

Description
Table of Contents
Request Sample

Description

This issue profiles a drug for oculopharyngeal muscular dystrophy treatment that receives orphan drug designation; non-viral CFTR-based gene therapy for cystic fibrosis patients, a breast cancer diagnostic test in Europe.

Genetic Technology Alert. Drug for Oculopharyngeal Muscular Dystrophy Treatment Receives Orphan Drug Designation; Non-Viral CFTR-Based Gene Therapy for Cystic Fibrosis Patients; Breast Cancer Diagnostic Test in Europe

In This Issue

1. DRUG FOR OCULOPHARYNGEAL MUSCULAR DYSTROPHY TREATMENT RECEIVES ORPHAN DRUG DESIGNATION
2. NON-VIRAL CFTR-BASED GENE THERAPY FOR CYSTIC FIBROSIS PATIENTS
3. BREAST CANCER DIAGNOSTIC TEST IN EUROPE
4. RECENT PATENTS IN GENETIC TESTS IN THE EUROPEAN UNION
5. TECHVISION 2015

Request Sample